Holy Stone Healthcare’s new drug, CA102N, for the treatment of colorectal cancer, has been granted a European Patent by the European Patent Office (EPO)

23, Jul 2021

Holy Stone Healthcare has established the Hyaluronan Drug Delivery (HDD) platform and has developed several novel Hyaluronic Acid conjugated drugs (HACD) based on it, including CA102N.  European Patent Office (EPO) has recently decided to grant a European Patent to HACD-CA102N, which covers CA102N for the treatment of colorectal cancer. This patent has been granted in many jurisdictions, including the United States, Australia, Japan, Eurasia, and India.

CA102N is a targeted anti-cancer drug with multiple MOAs in inhibiting tumor growth for the treatment of colorectal cancer.  Holy Stone Healthcare is currently conducting Phase I clinical trials of CA102N in the United States.

previous page